Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12564542 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL30468855 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL2848375 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL5896895 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL5896898 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL5897658 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL31064941 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL5897664 | 0.91 | ALDH1A1 (0.57) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL18544232 | 0.88 | EPHX1 (0.58) | ALDH1A1GAACPB1CTSBCTSK | |
| SCHEMBL13917140 | 0.88 | EPHX1 (0.58) | ALDH1A1GAACPB1CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | SYK, BTK, LYN | ALDH1A1 1660/4885GAA 2421/4885CPB1 3468/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.